About Agios Pharmaceuticals, Inc. - Common Stock (AGIO)
Agios Pharmaceuticals is a biopharmaceutical company focused on discovering and developing innovative therapies for genetically defined diseases, particularly in the fields of oncology and rare metabolic disorders. The company leverages its expertise in cellular metabolism and its proprietary drug discovery platform to create cutting-edge treatments that target the underlying causes of these diseases. Through a commitment to advancing science and improving the lives of patients, Agios aims to address unmet medical needs and bring transformative therapies to market. Read More
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results.
